Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD
| Autor: | Dave Singh, MeiLan K. Han, Jean Brooks, Robert A. Wise, Peter Lange, Frank Barnhart, Mark T. Dransfield, Steven Pascoe, Gerard J. Criner, Sally Kilbride, Maggie Tabberer, C. Elaine Jones, David M.G. Halpin, Fernando J. Martinez, Noushin Brealey, David A. Lipson, Nicola C. Day, David A. Lomas |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male medicine.medical_specialty Quinuclidines Muscarinic Antagonists Chlorobenzenes Gastroenterology Fluticasone propionate Drug Administration Schedule 03 medical and health sciences chemistry.chemical_compound Pulmonary Disease Chronic Obstructive 0302 clinical medicine Double-Blind Method Internal medicine Administration Inhalation Medicine Humans 030212 general & internal medicine Glucocorticoids Benzyl Alcohols Fluticasone Aged COPD Intention-to-treat analysis Inhalation business.industry Inhaler General Medicine Adrenergic beta-Agonists Middle Aged medicine.disease Bronchodilator Agents Intention to Treat Analysis Androstadienes Hospitalization Regimen Drug Combinations Dyspnea 030228 respiratory system chemistry Quality of Life Female Vilanterol business hormones hormone substitutes and hormone antagonists medicine.drug |
| Zdroj: | Singh, D & IMPACT Investigators 2018, ' Once-Daily Single Inhaler Triple Versus Dual Therapy in Patients with COPD ', The New England Journal of Medicine, vol. 378, pp. 1671-1678 . https://doi.org/10.1056/NEJMoa1713901 |
| ISSN: | 1533-4406 |
| Popis: | BACKGROUND The benefits of triple therapy for chronic obstructive pulmonary disease (COPD) with an inhaled glucocorticoid, a long-acting muscarinic antagonist (LAMA), and a long-acting β2-agonist (LABA), as compared with dual therapy (either inhaled glucocorticoid–LABA or LAMA–LABA), are uncertain. METHODS In this randomized trial involving 10,355 patients with COPD, we compared 52 weeks of a once-daily combination of fluticasone furoate (an inhaled glucocorticoid) at a dose of 100 μg, umeclidinium (a LAMA) at a dose of 62.5 μg, and vilanterol (a LABA) at a dose of 25 μg (triple therapy) with fluticasone furoate–vilanterol (at doses of 100 μg and 25 μg, respectively) and umeclidinium–vilanterol (at doses of 62.5 μg and 25 μg, respectively). Each regimen was administered in a single Ellipta inhaler. The primary outcome was the annual rate of moderate or severe COPD exacerbations during treatment. RESULTS The rate of moderate or severe exacerbations in the triple-therapy group was 0.91 per year, as compared with 1.07 per year in the fluticasone furoate–vilanterol group (rate ratio with triple therapy, 0.85; 95% confidence interval [CI], 0.80 to 0.90; 15% difference; P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|